| atezolizumab based treatment | anti-PD-(L)1 | durvalumab based treatment | nivolumab based treatment | pembrolizumab based treatment | sintilimab based treatment | anti-PD-(L)1 |
| atezolizumab plus bevacizumab | atezolizumab plus cabozantinib | camrelizumab based treatment | durvalumab plus bevacizumab | nivolumab alone | pembrolizumab alone | pembrolizumab plus lenvatinib | sintilimab | Tislelizumab |
mHCC - (neo)adjuvant (NA) 3 | | | | | | | | | |
mHCC - 1st line (L1) 10 | | | | | | | | | |
mHCC - 2nd line (L2) 2 | | | | | | | | | |